The estimated Net Worth of Ness W Denman Van is at least $628 Tysiąc dollars as of 15 March 2021. Mr. Van owns over 5,699 units of XOMA Royalty stock worth over $424,238 and over the last 22 years he sold XOMA stock worth over $3,029. In addition, he makes $200,992 as Independent Chairman of the Board at XOMA Royalty.
Sign up
Mr. Ness XOMA stock SEC Form 4 insiders trading
W has made over 11 trades of the XOMA Royalty stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 5,699 units of XOMA stock worth $59,327 on 15 March 2021.
The largest trade he's ever made was exercising 7,693 units of XOMA Royalty stock on 15 November 2018 worth over $52,697. On average, W trades about 1,194 units every 76 days since 2003. As of 15 March 2021 he still owns at least 15,643 units of XOMA Royalty stock.
You can see the complete history of Mr. Van stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
W. Denman Van Ness biography
W. Denman Van Ness serves as Independent Chairman of the Board of the Company. Mr. Van Ness has been a director since October of 1981 and was appointed Lead Independent Director in January of 2008 and Chairman of the Board in August of 2011. He is Chairman of Hidden Hill Advisors, a venture capital consulting firm. From April of 1996 through October of 1999, he was a Managing Director of CIBC Capital Partners, an international merchant banking organization. From 1986 to 1996, Mr. Van Ness was a General Partner of Olympic Venture Partners II and Rainier Venture Partners, venture capital funds, and from 1977 until 1985, he was a General Partner of the venture capital group at Hambrecht & Quist, the manager of several venture capital funds. Mr. Van Ness earned his B.A. in American History and Literature from Williams College and holds an MBA degree from Harvard University. Mr. Van Ness brings to the Board an extensive understanding of corporate development and a background in assessing a wide range of corporate funding sources and partnering opportunities. His leadership skills, including past service on the boards of other companies, contribute to his role as Chairman of the Board.
What is the salary of W Ness?
As the Independent Chairman of the Board of XOMA Royalty, the total compensation of W Ness at XOMA Royalty is $200,992. There are 5 executives at XOMA Royalty getting paid more, with James Neal having the highest compensation of $1,479,560.
How old is W Ness?
W Ness is 77, he's been the Independent Chairman of the Board of XOMA Royalty since 2011. There are no older and 8 younger executives at XOMA Royalty.
What's W Ness's mailing address?
Ness's mailing address filed with the SEC is C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, 94608.
Insiders trading at XOMA Royalty
Over the last 22 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... oraz Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
What does XOMA Royalty do?
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
What does XOMA Royalty's logo look like?
Complete history of Mr. Van stock trades at XOMA Royalty
XOMA Royalty executives and stock owners
XOMA Royalty executives and other stock owners filed with the SEC include:
-
James Neal,
Chief Executive Officer, Director -
Thomas Burns,
Chief Financial Officer, Senior Vice President - Finance -
James R. Neal,
CEO & Chairman -
Thomas M. Burns,
Sr. VP of Fin. & CFO -
Barbara Kosacz,
Independent Director -
W. Denman Van Ness,
Independent Chairman of the Board -
Jack Wyszomierski,
Independent Director -
Joseph Limber,
Independent Director -
Matthew Perry,
Independent Director -
Natasha Hernday,
Director -
Deepshikha Datta,
Chief Business Officer -
Timothy P Walbert,
Director -
Peter Barton Hutt,
Director -
Paul D Rubin,
VP Clinical Dev. & CMO -
Steven B Engle,
CEO and President -
Charles J Jr Fisher,
Director -
Patrick J Zenner,
Director -
John Varian,
Director -
Owen Hughes,
Chief Executive Officer -
Partners L P/Ilbiotechnolog...,
-
Fred Kurland,
VP Finance -
Thomas Klein,
Chief Commercial Officer -
William K Jr Bowes,
Director -
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lpbaker Feli...,
-
Bros Advisors Llcbaker Feli...,
-
Patrick J Md Phd Scannon,
CSMO -
Kelvin Neu,
Director -
Julianbaker Bros Advisors L...,
-
J David Ii Boyle,
VP, Finance, and CFO -
Arthur Md Kornberg,
Director -
John L Castello,
Chairman, CEO & President -
James G Andress,
Director -
Peter B Davis,
VP, Finance & CFO -
Clarence L Dellio,
Sr VP, Operations and COO -
Steven C Mendell,
Director -
Christopher J Margolin,
VP, General Counsel & Sec'y -
Partners L P/Ilbiotechnolog...,
-
Heather L Franklin,
-
Bradley Sitko,
Chief Investment Officer